Medicare Enrolled
Dr. Jagindra Mangru, MD
Rheumatology · Cumming, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mangru from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mangru?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mangru
Dr. Jagindra Mangru is a rheumatology specialist in Cumming, GA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Mangru performed 120,940 Medicare services across 1,730 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mangru received a total of $45,373 from 48 pharmaceutical and/or device companies across 1685 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mangru is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 9% volume in GA
$45,373 industry payments
Medicare Practice Summary
Medicare Utilization ↗120,940
Medicare services
Top 9% in GA for rheumatology
1,730
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~6,365 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) An injection of certolizumab pegol administered under the direct supervision of a physician. |
40,200 | $4 | $11 |
| Golimumab infusion (Simponi Aria) Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery. |
32,650 | $10 | $26 |
| Denosumab injection (Prolia/Xgeva) | 20,640 | $18 | $44 |
| Romosozumab injection (Evenity) for osteoporosis | 12,810 | $8 | $23 |
| Abatacept infusion (Orencia) An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered. |
7,150 | $34 | $87 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
4,120 | $24 | $69 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,037 | $93 | $270 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
666 | $57 | $189 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
415 | $105 | $345 |
| Steroid injection (triamcinolone) A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered. |
344 | $1 | $15 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
245 | $63 | $184 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
236 | $130 | $364 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
163 | $120 | $415 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
97 | $22 | $110 |
| Virtual check-in for established patient A brief communication service provided by a qualified healthcare professional to an established patient via technology, such as a virtual check-in. |
75 | $10 | $32 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
53 | $9 | $64 |
| Methylprednisolone acetate injection, 80 mg An injection of 80 mg of methylprednisolone acetate, a corticosteroid medication. |
15 | $9 | $40 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
12 | $91 | $273 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
12 | $105 | $345 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
36.7% high complexity
61.9% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$45,373
Total received (2018-2024)
Avg $6,482/year across 7 years
Top 8% in GA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
48
Companies
1,685
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$29,734 (65.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$9,729 (21.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,909 (13.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$14,812
2023
$5,513
2022
$7,966
2021
$5,271
2020
$2,971
2019
$4,768
2018
$4,071
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$9,502
ABBVIE INC.
$1,123
Amgen Inc.
$888
UCB, Inc.
$520
Janssen Biotech, Inc.
$443
Mallinckrodt Hospital Products Inc.
$250
Novartis Pharmaceuticals Corporation
$247
PFIZER INC.
$245
Radius Health, Inc.
$243
GlaxoSmithKline, LLC.
$235
E.R. Squibb & Sons, L.L.C.
$189
Lilly USA, LLC
$173
Alexion Pharmaceuticals, Inc.
$143
ANI Pharmaceuticals, Inc.
$138
SOBI, INC
$118
Aurinia Pharma U.S., Inc.
$81
Boehringer Ingelheim Pharmaceuticals, Inc.
$57
Sandoz Inc.
$54
Organon Llc
$46
GENZYME CORPORATION
$26
Actelion Pharmaceuticals US, Inc.
$22
Pacira Pharmaceuticals Incorporated
$21
Boston Scientific Corporation
$19
IBSA Pharma Inc.
$14
Kiniksa Pharmaceuticals International, plc
$13
Top 3 companies account for 77.7% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$10,151
UCB, Inc.
$5,718
Amgen Inc.
$4,978
ABBVIE INC.
$2,821
Janssen Biotech, Inc.
$2,778
Novartis Pharmaceuticals Corporation
$2,196
PFIZER INC.
$1,886
Lilly USA, LLC
$1,515
Horizon Therapeutics plc
$1,361
Mallinckrodt Hospital Products Inc.
$1,196
GENZYME CORPORATION
$1,154
AbbVie Inc.
$999
GlaxoSmithKline, LLC.
$962
AbbVie, Inc.
$917
Boehringer Ingelheim Pharmaceuticals, Inc.
$858
Radius Health, Inc.
$806
E.R. Squibb & Sons, L.L.C.
$788
Genentech USA, Inc.
$782
Aurinia Pharma U.S., Inc.
$623
ANI Pharmaceuticals, Inc.
$388
Horizon Pharma plc
$242
SOBI, INC
$241
Celgene Corporation
$237
SANOFI-AVENTIS U.S. LLC
$227
Mallinckrodt LLC
$168
Alexion Pharmaceuticals, Inc.
$160
Antares Pharma, Inc.
$156
Mallinckrodt Enterprises LLC
$144
Sobi, Inc
$138
Sandoz Inc.
$115
Flexion Therapeutics, Inc.
$104
Janssen Scientific Affairs, LLC
$79
Exeltis, USA Inc.
$62
Merck Sharp & Dohme Corporation
$56
Takeda Pharmaceuticals U.S.A., Inc.
$55
MEDEXUS PHARMA, INC.
$46
Organon Llc
$46
Organon LLC
$39
MEDAC PHARMA, INC.
$27
Actelion Pharmaceuticals US, Inc.
$22
Pacira Pharmaceuticals Incorporated
$21
Boston Scientific Corporation
$19
Kiniksa Pharmaceuticals, Ltd.
$19
Gilead Sciences, Inc.
$17
Oxford Immunotec USA Inc
$15
IBSA Pharma Inc.
$14
Kiniksa Pharmaceuticals International, plc
$13
Ironwood Pharmaceuticals, Inc
$13
Top 3 companies account for 45.9% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · Arcalyst · BENLYSTA · Bimzelx · COLOGUARD DNA CAPTURE REAGENTS · COSENTYX · CUVITRU · Cimzia · DUEXIS · DUZALLO · EVENITY · Enbrel · FORTEO · HADLIMA · HUMIRA · HYRIMOZ · Humira · INFLECTRA · KEVZARA · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · OPSUMIT · ORENCIA · OTREXUP · Otezla · Otrexup · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · RENFLEXIS · REYVOW · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TREMFYA · TSPOT TB TEST · Tavneos · Tirosint · Tymlos · Uloric · VIMOVO · XELJANZ · XYOSTED · Zilretta
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (66%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 8% for rheumatology in GA.
Geographic Context
Rheumatologists within 10 mi
41
Per 100K population
15.8
County median income
$138,000
Nearest hospital
NORTHSIDE HOSPITAL FORSYTH
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mangru is a mixed practice specialist, with above-average Medicare volume (top 9% in GA), with low-engagement industry engagement in the top 8% of GA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mangru experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Mangru performed 40,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mangru receive payments from pharmaceutical companies?
Yes. Dr. Mangru received a total of $45,373 from 48 companies across 1,685 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mangru's costs compare to other rheumatologists in Cumming?
Dr. Mangru's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mangru) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Rheumatologists in Cumming
Browse rheumatologists in Cumming ranked by procedure volume and transparency data.
Highest volume
Top Rheumatologists in GA
Rheumatologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Rheumatologists in GA
Which GA rheumatologists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
UCB, Inc. Payments to Doctors
See all physicians who received payments from UCB, Inc.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology